Schleiss M. R., and Heineman T. C. 2005. Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev Vaccines 4:381–406. pmid:16026251 doi: 10.1586/14760584.4.3.381
[2]
Boppana S. B., Ross S. A., and Fowler K. B. 2013. Congenital cytomegalovirus infection: clinical outcome. Clin Infect Dis 57: Suppl 4 S178–S181. doi: 10.1093/cid/cit629. pmid:24257422
[3]
Lilleri D., Fornara C., Furione M., Zavattoni M., Revello M.G., and Gerna G. 2007. Development of human cytomegalovirus-specific T cell immunity during primary infection of pregnant women and its correlation with virus transmission to the fetus. J Infect Dis 195: 1062–1070. doi: 10.1086/512245. pmid:17330798
[4]
Boppana S. B. and Britt W. J. 1995. Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J Infect Dis 171:1115–1121. doi: 10.1093/infdis/171.5.1115. pmid:7751685
[5]
Lilleri D., Kabanova A., Revello M. G., Percivalle E., Sarasini A., Genini E, Sallusto F., Lanzavecchia A., Corti D. and Gerna G. 2013. Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection. PLoS ONE. 8:e59863. doi: 10.1371/journal.pone.0059863. pmid:23555812
[6]
Rieder F. and Steininger C. 2014. Cytomegalovirus vaccine: phase II clinical trial results. Clin Microbiol Infect 20:95–102. doi: 10.1111/1469-0691.12449. pmid:24283990
[7]
Adler S. P., Plotkin S. A., Gonczol E., Cadoz M., Meric C., Wang J. B., Dellamonica P., Best A. M. Zahradnik J., Pincus S., Berencsi K., Cox W. I and Gyulai Z. 1999. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis 180: 843–846. doi: 10.1086/314951. pmid:10438376
[8]
Berensci K, Gyulai Z., Gonczol E., Pincus S., Cox W. I., Michelson S., Kari L., Meric C., Cadoz M., Zahradnik J., Starr S. and Plotkin S. 2001. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis 183: 1171–1179. doi: 10.1086/319680. pmid:11262198
[9]
Smith L. R., Wlock M. K., Chaplin J. A., Gerber M. and Rolland A. P. 2013. Clinical development of a cytomegalovirus DNA vaccine: from product concept to a pivotal phase 3 trial. Vaccines. 398–414. doi: 10.3390/vaccines1040398. pmid:26344340
[10]
Nigro G, Adler S, La Torre R, Best AM. 2005. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med. 353: 1350–1362. pmid:16192480 doi: 10.1056/nejmoa043337
[11]
Revello M. G., Lazzarotto T., Guerra B, Spinillo A., Ferrazzi E., Kustermann A., Guaschino S., Vergani P., Todros T., Frusca T., Arossa A., Furione M., Rognoni V., Rizzo N., Gabrielli L., Klersy C., and Gerna G. 2014. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med. 370: 1316–1326. doi: 10.1056/NEJMoa1310214. pmid:24693891
[12]
Leviton M. P., Lacayo J. C., Choi K. Y., Hernandez-Alvarado N., Wey A., and Schleiss M. R. 2013. An attenuated cytomegalovirus vaccine with a deletion of a viral chemokine gene is protective against congenital CMV transmission in a guinea pig model. Clin Dev Immunol 2013:906948. doi: 10.1155/2013/906948. pmid:24000289
[13]
Schleiss M. R., Lacayo J. C., Belkaid Y., McGregor A., Stroup G., Rayner J., Alterson K., Chulay J. D., and Smith J. F. 2007. Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. J Infect Dis 195:789–798. doi: 10.1086/511982. pmid:17299708
[14]
Berstein D. I., Reap E. A., Katen K., Watson A., Smith K., Norberg P., Olmsted R. A., Hoeper A., Morris J., Negri S., Maughan M. F., and Chulay J. D. 2010. Randomized, double-blind, Phase I trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine. 28:484–493. doi: 10.1016/j.vaccine.2009.09.135.
[15]
Wloch M. K., Smith L. R., Boutsaboualoy S., Reyes S., Han C., Kehler J., Smith H. D., Selk L., Nakamura R., Brown J. M., Marbury T., Wald A., Rolland A., Kaslow D., Evans T., Boeckh M. 2008. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis 197:1634–1642. doi: 10.1086/588385. pmid:18444883
[16]
Jacobson M. A., Adler S. P., Sinclair E., Black D., Smith A., Chu A., Moss R. B., and Wloch M. K. 2009. A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain). Vaccine. 27:1540–1548. doi: 10.1016/j.vaccine.2009.01.006. pmid:19168107
[17]
Chatterjee A., Harrison C. J., Britt W. J., and Bewtra C. 2001. Modification of maternal and congenital cytomegalovirus infection by anti-glycoprotein B antibody transfer in guinea pigs. J Infect Dis 183:1547–1553. doi: 10.1086/320714. pmid:11343203
[18]
Auerback M. R., Yan D., Vij R., Hongo J., Nakamura G., Vernes J., Meng Y. G., Lein S., Chan P., Ross J., Carano R., Deng R., Lewin-Koh N., Xu M., and Feierbach B. 2014. A neutralizing anti-gH/gL monoclonal antibody is protective in the guinea pig model of congenital CMV infection. PLoS Pathog. 10:e1004060. doi: 10.1371/journal.ppat.1004060. pmid:24722349
[19]
Bialas K. M., Tanaka T., Tran D., Varner V., de la Rosa E. C., Chiuppesi F., Wussow F., Kattenhorn L., Macri S., Kunz E. L., Estroff J. A., Kirchherr J., Yue Y., Fan Q., Lauc M., O’Connor D. H., Hall A., Xavier A., Diamond D. J., Barry P. A., Kaur A., and Permar S. R. 2015. Maternal CD4+ T cells protect against severe congenital CMV disease in a novel nonhuman primate model of placental CMV transmission. Proc Natl Acad Sci U S A;112(44):13645–50. pmid:26483473 doi: 10.1073/pnas.1511526112
[20]
Tarantal A. F., Salamat M. S., Britt W. J., Luciw P. A., Henrickx A. G. and Barry P. A. 1998. Neuropathogenesis induced by rhesus cytomegalovirus in fetal rhesus monkeys (Macaca mulatta). J Infect Dis 177:446–450. doi: 10.1086/514206. pmid:9466534
